UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma

Blood advances, 2021-10, Vol.5 (20), p.4059-4063

2021

Volltextzugriff (PDF)

Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm

Hematology/oncology clinics of North America, 2020-06, Vol.34 (3), p.575-587

2020

Volltextzugriff (PDF)

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia

Blood, 2013-10, Vol.122 (18), p.3138-3148

2013

Volltextzugriff (PDF)

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Blood, 2023-10, Vol.142 (16), p.1359-1370

2023

Volltextzugriff (PDF)

Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis

Blood advances, 2023-02, Vol.7 (4), p.533-536

2023

Volltextzugriff (PDF)

Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy

Journal of the National Comprehensive Cancer Network, 2023-04, Vol.21 (4), p.373-382.e1

2023

Volltextzugriff (PDF)

Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies

Blood advances, 2024-08, Vol.8 (15), p.4066-4076

2024

Volltextzugriff (PDF)

IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S387

2022

Volltextzugriff (PDF)

Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy

Transplantation and cellular therapy, 2024-09, Vol.30 (9), p.927.e1-927.e9

2024

Volltextzugriff (PDF)

S220: REAL‐WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU‐CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT

HemaSphere, 2023-08, Vol.7 (S3), p.e43327c1-n/a

2023

Volltextzugriff (PDF)

Acute myeloid leukemia therapeutics: CARs in the driver's seat

Oncoimmunology, 2013-12, Vol.2 (12), p.e27214-e27214

2013

Volltextzugriff (PDF)

Acrue: A Phase 2, Open-Label Study of Acalabrutinib in Combination with Rituximab in Elderly and/or Frail Patients with Treatment-Naive Diffuse Large B-Cell Lymphoma

Blood, 2023-11, Vol.142 (Supplement 1), p.6246-6246

2023

Volltextzugriff (PDF)

A Phase 1b Dose Expansion Study Evaluating Safety, Preliminary Anti-Tumor Activity, and Accelerated T Cell Reconstitution with NT-I7 (Efineptakin Alfa), a Long-Acting Human IL-7, Administered Following Tisagenlecleucel in Subjects with Relapsed/Refractory Large B-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.10366-10367

2022

Volltextzugriff (PDF)

Trial in progress: A phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS7596-TPS7596

2022

Volltextzugriff (PDF)

Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma

Haematologica (Roma), 2024-02, Vol.109 (2), p.533

2024

Volltextzugriff (PDF)

The Combination of Nivolumab and CC-486 Is Active in Hodgkin Lymphoma Refractory to PD-1 Blockade

Blood, 2023-11, Vol.142 (Supplement 1), p.1697-1697

2023

Volltextzugriff (PDF)

Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation

Blood, 2023-11, Vol.142 (Supplement 1), p.614-614

2023

Volltextzugriff (PDF)

Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results from the Phase II Morningsun Study

Blood, 2023-11, Vol.142 (Supplement 1), p.3029-3029

2023

Volltextzugriff (PDF)

Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study

Blood, 2023-11, Vol.142 (Supplement 1), p.734-734

2023

Volltextzugriff (PDF)

CD19-Directed CAR T-Cells (CD19-CAR) Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL)

Blood, 2023-11, Vol.142 (Supplement 1), p.4840-4840

2023

Volltextzugriff (PDF)

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.221-221

2023

Volltextzugriff (PDF)

Clonal Hematopoiesis Is Associated with Severe Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Blood, 2023-11, Vol.142 (Supplement 1), p.4814-4814

2023

Volltextzugriff (PDF)

Phase 1 Study of SC291, a Hypoimmune, Allogeneic CD19-Directed CAR T Cell Therapy for Relapsed/Refractory B-Cell Malignancies (ARDENT) - Initial Clinical Data

Blood, 2023-11, Vol.142 (Supplement 1), p.6852-6852

2023

Volltextzugriff (PDF)

1 – 25 von 115

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(86)

Publikationsform

Artikel
(114)
Tagungsberichte
(1)

Sprache

Englisch
(115)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Humans
(24)
Hematology
(15)
Adult
(7)
Aged
(5)
Follicular Lymphoma
(5)
Ibcl
(5)
Immunotherapy, Adoptive
(5)
Clinical Neurology
(4)
Genome-Wide Association Study
(4)
Immunology
(4)
Lymphoma, Large B-Cell, Diffuse - Drug Therapy
(4)
Middle Aged
(4)
Mosunetuzumab
(4)
Neurosciences & Neurology
(4)
Oncology
(4)
Bispecific Antibody
(3)
Female
(3)
Genetics
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma

Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis

Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy

Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies

IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study

Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy

S220: REAL‐WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU‐CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT

P1078: MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED AND/OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY

Acute myeloid leukemia therapeutics: CARs in the driver's seat

Acrue: A Phase 2, Open-Label Study of Acalabrutinib in Combination with Rituximab in Elderly and/or Frail Patients with Treatment-Naive Diffuse Large B-Cell Lymphoma

A Phase 1b Dose Expansion Study Evaluating Safety, Preliminary Anti-Tumor Activity, and Accelerated T Cell Reconstitution with NT-I7 (Efineptakin Alfa), a Long-Acting Human IL-7, Administered Following Tisagenlecleucel in Subjects with Relapsed/Refractory Large B-Cell Lymphoma

Trial in progress: A phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma

Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma

The Combination of Nivolumab and CC-486 Is Active in Hodgkin Lymphoma Refractory to PD-1 Blockade

Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation

Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results from the Phase II Morningsun Study

Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study

CD19-Directed CAR T-Cells (CD19-CAR) Combined with Acalabrutinib Achieves Durable Remissions in Patients with Relapsed or Refractory (r/r) Mantle Cell Lymphoma (MCL)

Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study

Clonal Hematopoiesis Is Associated with Severe Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Phase 1 Study of SC291, a Hypoimmune, Allogeneic CD19-Directed CAR T Cell Therapy for Relapsed/Refractory B-Cell Malignancies (ARDENT) - Initial Clinical Data

Suchergebnisse filtern